11208854

Source:http://linkedlifedata.com/resource/pubmed/id/11208854

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0027627, umls-concept:C0030705, umls-concept:C0205269, umls-concept:C0442027, umls-concept:C0763138, umls-concept:C0920321, umls-concept:C1513016
pubmed:issue	2
pubmed:dateCreated	2001-3-6
pubmed:abstractText	This phase I clinical trial was designed to determine the maximum-tolerated dose and dose-limiting toxicities of the matrix metalloproteinase (MMP) inhibitor COL-3 in patients with refractory solid tumors.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Endothelial Growth Factors, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Fibroblast Growth Factor 2, http://linkedlifedata.com/resource/pubmed/chemical/Lymphokines, http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 2, http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 9, http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinases, http://linkedlifedata.com/resource/pubmed/chemical/Tetracyclines, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factors, http://linkedlifedata.com/resource/pubmed/chemical/tetracycline CMT-3
pubmed:status	MEDLINE
pubmed:month	Jan
pubmed:issn	0732-183X
pubmed:author	pubmed-author:CoteEE, pubmed-author:DahutWW, pubmed-author:DyerVV, pubmed-author:KohlerD RDR, pubmed-author:LiewehrD JDJ, pubmed-author:PludaJ MJM, pubmed-author:ReedEE, pubmed-author:RudekM AMA, pubmed-author:SteinbergS MSM, pubmed-author:TurnerM LML
pubmed:issnType	Print
pubmed:day	15
pubmed:volume	19
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	584-92
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:11208854-Adult, pubmed-meshheading:11208854-Aged, pubmed-meshheading:11208854-Antineoplastic Agents, pubmed-meshheading:11208854-Endothelial Growth Factors, pubmed-meshheading:11208854-Enzyme Inhibitors, pubmed-meshheading:11208854-Female, pubmed-meshheading:11208854-Fibroblast Growth Factor 2, pubmed-meshheading:11208854-Humans, pubmed-meshheading:11208854-Lymphokines, pubmed-meshheading:11208854-Male, pubmed-meshheading:11208854-Matrix Metalloproteinase 2, pubmed-meshheading:11208854-Matrix Metalloproteinase 9, pubmed-meshheading:11208854-Matrix Metalloproteinases, pubmed-meshheading:11208854-Middle Aged, pubmed-meshheading:11208854-Neoplasms, pubmed-meshheading:11208854-Statistics, Nonparametric, pubmed-meshheading:11208854-Tetracyclines, pubmed-meshheading:11208854-Vascular Endothelial Growth Factor A, pubmed-meshheading:11208854-Vascular Endothelial Growth Factors
pubmed:year	2001
pubmed:articleTitle	Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.
pubmed:affiliation	Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Clinical Trial, Phase I